iOnctura mission is to develop high impact, low disruption therapies that extend health span by disrupting the dynamic interplay of the tumor-stroma-immune interface. First targets are neglected and hard to treat cancers where conventional therapies come with side effects that are as severe as the disease itself. Challenging the status quo, iOnctura develops more effective, less toxic treatments. Rigonolisib (Pi3Kd inhibitor) and Cambritaxestat (autotaxin inhibitor), IOA359 (TGFb) are in advanced clinical programs that push the boundaries of conventional therapies, combatting resistance in both solid and hematological cancers.